|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,450.00 KRW | -6.71% |
|
-8.44% | -34.75% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 25-06-12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
Net Income | 293M | -3.76B | -550M | -1.26B | 4.04B | ||
Depreciation & Amortization - CF | 1.98B | 2.72B | 3.45B | 3.13B | 2.76B | ||
Amortization of Goodwill and Intangible Assets - (CF) | 76.48M | 84.28M | 90.07M | 94.39M | 102M | ||
Depreciation & Amortization, Total | 2.06B | 2.81B | 3.54B | 3.22B | 2.87B | ||
(Gain) Loss From Sale Of Asset | 13.83M | 44.89M | -1.57M | -1.36M | 139M | ||
(Gain) Loss on Sale of Investments - (CF) | - | - | - | - | -1.83B | ||
Asset Writedown & Restructuring Costs | - | - | - | 1.13B | - | ||
(Income) Loss On Equity Investments - (CF) | - | 2.93M | - | - | -553M | ||
Stock-Based Compensation (CF) | - | - | - | - | 586M | ||
Provision and Write-off of Bad Debts | 29.55M | -6.17M | -4.25M | 7.42M | 84.68M | ||
Other Operating Activities, Total | -1.22B | 1.9B | 1.7B | -177M | -60.97M | ||
Change In Accounts Receivable | -2.13B | -518M | -83.41M | -1.13B | -1.64B | ||
Change In Inventories | -610M | -618M | 30.87M | -97.71M | -802M | ||
Change In Accounts Payable | 1.29B | 17.83M | -460M | -852M | - | ||
Change in Unearned Revenues | - | - | - | - | - | ||
Change in Other Net Operating Assets | 208M | -1.47B | -834M | -457M | -1.54B | ||
Cash from Operations | -67.7M | -1.61B | 3.34B | 378M | 1.3B | ||
Capital Expenditure | -2.87B | -4.03B | -7.41B | -329M | -311M | ||
Sale of Property, Plant, and Equipment | - | 814M | - | - | 5.86M | ||
Sale (Purchase) of Intangible assets | -169M | -40.7M | -49.42M | -87.11M | -42.99M | ||
Investment in Marketable and Equity Securities, Total | 5.24B | 8.95B | -4.97B | 3.82B | -11.95B | ||
Other Investing Activities, Total | -303M | -517M | -55.46M | -276M | -184M | ||
Cash from Investing | 1.9B | 5.18B | -12.48B | 3.13B | -12.48B | ||
Short Term Debt Issued, Total | - | - | - | - | - | ||
Long-Term Debt Issued, Total | - | - | - | - | - | ||
Total Debt Issued | - | - | - | - | - | ||
Short Term Debt Repaid, Total | - | - | - | - | - | ||
Long-Term Debt Repaid, Total | -490M | -672M | -859M | -616M | -664M | ||
Total Debt Repaid | -490M | -672M | -859M | -616M | -664M | ||
Issuance of Common Stock | - | - | - | - | 40.44B | ||
Cash from Financing | -490M | -672M | -859M | -616M | 39.77B | ||
Foreign Exchange Rate Adjustments | - | -994K | -5.41M | 5.69K | 38.6K | ||
Miscellaneous Cash Flow Adjustments | 10 | - | - | - | - | ||
Net Change in Cash | 1.34B | 2.89B | -10B | 2.89B | 28.59B | ||
Supplemental Items | |||||||
Cash Interest Paid | 30.66M | - | 173M | 211M | 186M | ||
Cash Income Tax Paid (Refund) | 31.28M | -54.92M | -3.1M | -2.53M | 58.45M | ||
Levered Free Cash Flow | -3.85B | -933M | -7.6B | -3B | -1.05B | ||
Unlevered Free Cash Flow | -2.92B | 126M | -7.02B | -2.4B | -932M | ||
Change In Net Working Capital | 621M | -3.41B | 3.21B | 4.43B | 4.22B | ||
Net Debt Issued / Repaid | -490M | -672M | -859M | -616M | -664M |
Select your edition
All financial news and data tailored to specific country editions
















